1,635 research outputs found
Postoperative pain after arthroscopic versus open rotator cuff repair. A prospective study
Introduction: Although the arthroscopic technique is becoming the gold standard for rotator cuff tendon repair, there is no proof that this technique results in less postoperative pain compared to open repair. The aim of this study was to prospectively compare the postoperative pain level after arthroscopic or open rotator cuff repair and to define factors that could influence its course. Materials and methods: Between January 2012 and January 2013, 95 patients were operated for a rotator cuff tear: 45 using an arthroscopic technique and 50 an open technique. Daily analgesic use and self-evaluation of pain level using a visual analogic scale were recorded preoperatively and twice a day postoperatively during the first 6 weeks. These data were compared between the two groups and analyzed according to patients’ demographic data and preoperative evaluation of the tear. Results: The preoperative pain level was equivalent in the two groups (P = 0.22). Postoperatively, level-2 analgesic medication use was greater in the arthroscopic group after the 4th week (P = 0.01). A painfree shoulder was obtained before the 6th week in 75% and 66% of the patients after arthroscopic or open repair, respectively (P = 0.34). There was a positive correlation between the preoperative and postoperative pain level (r = 0.25; P = 0.02). Work compensation patients experienced more pain postoperatively (P = 0.08). Level-III analgesic medication use was greater for patients with massive rotator cuff tear (P = 0.001). Conclusion: No evidence was found on the superiority of arthroscopy versus open repair of rotator cuff tear concerning the postoperative pain level. The choice of the surgical technique should not be based on this argument
Differential Seroprevalence of Human Bocavirus Species 1-4 in Beijing, China
BACKGROUND: Four species of human bocaviruses (HBoV1-4) have been identified based on phylogenetic analysis since its first report in 2005. HBoV1 has been associated with respiratory disease, whereas HBoV2-4 are mainly detected in enteric infections. Although the prevalence of HBoVs in humans has been studied in some regions, it has not been well addressed globally. METHODOLOGY/PRINCIPAL FINDINGS: Cross-reactivity of anti-VP2 antibodies was detected between HBoV1, 2, 3, and 4 in mouse and human serum. The prevalence of specific anti-VP2 IgG antibodies against HBoV1-4 was determined in different age groups of healthy individuals aged 0-70 years old in Beijing, China, using a competition ELISA assay based on virus-like particles of HBoV1-4. The seroprevalence of HBoV1-4 was 50%, 36.9%, 28.7%, and 0.8%, respectively, in children aged 0-14 years (n = 244); whereas the seroprevalence of HBoV1-4 was 66.9%, 49.3%, 38.7% and 1.4%, respectively, in healthy adults (≥ 15 years old; n = 142). The seropositive rate of HBoV1 was higher than that of HBoV2, HBoV3, and HBoV4 in individuals older than 0.5 years. Furthermore, IgG seroconversion of HBoV1 (10/31, 32.3%), HBoV2 (8/31, 25.8%), and HBoV3 (2/31, 6.5%) was found in paired sera collected from children with respiratory tract infections who were positive for HBoV1 according to PCR analysis. CONCLUSIONS/SIGNIFICANCE: Our data indicate that HBoV1 is more prevalent than HBoV2, HBoV3, and HBoV4 in the population we sampled in Beijing, China, suggesting that HBoV species may play differential roles in disease
DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery
To address the increasing need for detecting and validating protein biomarkers in clinical specimens, mass spectrometry (MS)-based targeted proteomic techniques, including the selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and massively parallel data-independent acquisition (DIA), have been developed. For optimal performance, they require the fragment ion spectra of targeted peptides as prior knowledge. In this report, we describe a MS pipeline and spectral resource to support targeted proteomics studies for human tissue samples. To build the spectral resource, we integrated common open-source MS computational tools to assemble a freely accessible computational workflow based on Docker. We then applied the workflow to generate DPHL, a comprehensive DIA pan-human library, from 1096 data-dependent acquisition (DDA) MS raw files for 16 types of cancer samples. This extensive spectral resource was then applied to a proteomic study of 17 prostate cancer (PCa) patients. Thereafter, PRM validation was applied to a larger study of 57 PCa patients and the differential expression of three proteins in prostate tumor was validated. As a second application, the DPHL spectral resource was applied to a study consisting of plasma samples from 19 diffuse large B cell lymphoma (DLBCL) patients and 18 healthy control subjects. Differentially expressed proteins between DLBCL patients and healthy control subjects were detected by DIA-MS and confirmed by PRM. These data demonstrate that the DPHL supports DIA and PRM MS pipelines for robust protein biomarker discovery. DPHL is freely accessible at https://www.iprox.org/page/project.html?id=IPX0001400000
Measurements of the branching fractions for decays at Belle II
This paper reports a study of decays using
fb of data collected during 2019--2020 by the Belle II experiment at the
SuperKEKB asymmetric-energy collider, corresponding to events. We find , ,
, and signal events in the decay modes , ,
, and , respectively. The uncertainties quoted for the
signal yield are statistical only. We report the branching fractions of these
decays: where the first
uncertainty is statistical, and the second is systematic. The results are
consistent with world-average values
Angular analysis of decays reconstructed in 2019, 2020, and 2021 Belle II data
We report on a Belle II measurement of the branching fraction
(), longitudinal polarization fraction (), and CP asymmetry
() of decays. We reconstruct decays in a
sample of SuperKEKB electron-positron collisions collected by the Belle II
experiment in 2019, 2020, and 2021 at the (4S) resonance and
corresponding to 190 fb of integrated luminosity. We fit the
distributions of the difference between expected and observed candidate
energy, continuum-suppression discriminant, dipion masses, and decay angles of
the selected samples, to determine a signal yield of events. The
signal yields are corrected for efficiencies determined from simulation and
control data samples to obtain $\mathcal{B}(B^+ \to \rho^+\rho^0) = [23.2^{+\
2.2}_{-\ 2.1} (\rm stat) \pm 2.7 (\rm syst)]\times 10^{-6}f_L = 0.943 ^{+\
0.035}_{-\ 0.033} (\rm stat)\pm 0.027(\rm syst)\mathcal{A}_{CP}=-0.069
\pm 0.068(\rm stat) \pm 0.060 (\rm syst)\mathcal{A}_{CP}B^+\to
\rho^+\rho^0$ decays reported by Belle II
Determination of from untagged decays using 2019-2021 Belle II data
We present an analysis of the charmless semileptonic decay , where , from 198.0 million pairs of
mesons recorded by the Belle II detector at the SuperKEKB
electron-positron collider. The decay is reconstructed without identifying the
partner meson. The partial branching fractions are measured independently
for and as functions of
(momentum transfer squared), using 3896 and
5466 decays. The total branching fraction is
found to be for decays, where the uncertainties are statistical and
systematic, respectively. By fitting the measured partial branching fractions
as functions of , together with constraints on the nonperturbative
hadronic contribution from lattice QCD calculations, the magnitude of the
Cabibbo-Kobayashi-Maskawa matrix element , , is extracted. Here, the first uncertainty is
statistical, the second is systematic and the third is theoretical
Observation of decays using the 2019-2022 Belle II data sample
We present a measurement of the branching fractions of four decay modes. The measurement is based on data from
SuperKEKB electron-positron collisions at the resonance
collected with the Belle II detector and corresponding to an integrated
luminosity of . The event yields are extracted from fits
to the distributions of the difference between expected and observed meson
energy to separate signal and background, and are efficiency-corrected as a
function of the invariant mass of the system. We find the branching
fractions to be: where the first uncertainty is statistical and
the second systematic. These results include the first observation of
, , and decays and a significant improvement in the precision
of compared to previous measurements
Measurement of the branching fraction for the decay at Belle II
We report a measurement of the branching fraction of decays, where or
, using electron-positron collisions recorded at an energy at or near
the mass and corresponding to an integrated luminosity of
fb. The data was collected during 2019--2021 by the Belle II experiment
at the SuperKEKB asymmetric-energy collider. We reconstruct
candidates in the , , and
final states. The signal yields with statistical uncertainties are ,
, and for the decays , , and , respectively.
We measure the branching fractions of these decays for the entire range of the
dilepton mass, excluding the very low mass region to suppress the background and regions compatible with decays
of charmonium resonances, to be \begin{equation} {\cal B}(B \to
K^{\ast}(892)\mu^+\mu^-) = (1.19 \pm 0.31 ^{+0.08}_{-0.07}) \times 10^{-6},
{\cal B}(B \to K^{\ast}(892)e^+e^-) = (1.42 \pm 0.48 \pm 0.09)\times 10^{-6},
{\cal B}(B \to K^{\ast}(892)\ell^+\ell^-) = (1.25 \pm 0.30 ^{+0.08}_{-0.07})
\times 10^{-6}, \end{equation} where the first and second uncertainties are
statistical and systematic, respectively. These results, limited by sample
size, are the first measurements of branching
fractions from the Belle II experiment
- …